Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/20/20
End: 12/16/22
Due: 12/16/23
Phase: N/A
Priority: Normal
Start: 07/07/17
End: 03/10/21
Due: 03/10/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients | NCT04364035 | Aelix Therapeutics | user2@example.com | None | 2020-02-20 | 2022-12-16 | 2023-12-16 | - | - | 2025-07-14 |
| Safety and Immunogenicity Study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002) | NCT03204617 | Aelix Therapeutics | user2@example.com | None | 2017-07-07 | 2021-03-10 | 2022-03-10 | - | - | 2025-07-14 |